AnTolRx Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

AnTolRx General Information

Description

Developer of novel nanoformulation-based therapies designed to treat autoimmune diseases. The company's drug development approach selectively targets pathogenic immune cells providing a different tolerogenic signal to induce an anti-inflammatory phenotype and convenient treat diseases and focus on the fields of diabetes, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, enabling healthcare professionals to provide efficacy and safety treatment for patients without suppressing the immune system and inducing side effects.

Contact Information

Website
www.antolrx.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • One Kendall Square, Building 1400 West
  • Suite 14303
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • One Kendall Square, Building 1400 West
  • Suite 14303
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnTolRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Mar-2024 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 08-Sep-2016 Completed Pre-Clinical Trials
To view AnTolRx’s complete valuation and funding history, request access »

AnTolRx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view AnTolRx’s complete cap table history, request access »

AnTolRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel nanoformulation-based therapies designed to treat autoimmune diseases. The company's drug development
Drug Discovery
Cambridge, MA

Basel, Switzerland

Geneva, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AnTolRx Competitors (36)

One of AnTolRx’s 36 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Baliopharm Venture Capital-Backed Basel, Switzerland
Amal Therapeutics Formerly VC-backed Geneva, Switzerland
CuraVac Formerly Accelerator/Incubator backed Rixensart, Belgium
Imcare Biotech Venture Capital-Backed Doylestown, PA
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
You’re viewing 5 of 36 competitors. Get the full list »

AnTolRx Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

AnTolRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020315432-A1 Immune tolerization agents and potentiators Inactive 16-Jul-2019
EP-3999054-A1 Immune tolerization agents and potentiators Inactive 16-Jul-2019
EP-3999054-A4 Immune tolerization agents and potentiators Inactive 16-Jul-2019
US-20220387398-A1 Immune tolerization agents and potentiators Inactive 16-Jul-2019
WO-2021011806-A1 Immune tolerization agents and potentiators Inactive 16-Jul-2019 A61K31/427
To view AnTolRx’s complete patent history, request access »

Ready to get started?

Request a free trial

AnTolRx FAQs

  • When was AnTolRx founded?

    AnTolRx was founded in 2015.

  • Where is AnTolRx headquartered?

    AnTolRx is headquartered in Cambridge, MA.

  • What industry is AnTolRx in?

    AnTolRx’s primary industry is Drug Discovery.

  • Is AnTolRx a private or public company?

    AnTolRx is a Private company.

  • What is AnTolRx’s current revenue?

    The current revenue for AnTolRx is .

  • How much funding has AnTolRx raised over time?

    AnTolRx has raised $4M.

  • Who are AnTolRx’s competitors?

    Baliopharm, Amal Therapeutics, CuraVac, Imcare Biotech, and NGM Biopharmaceuticals are some of the 36 competitors of AnTolRx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process